About Shattuck Labs, Inc.
https://www.shattucklabs.comShattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
CEO
Taylor H. Schreiber
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 16
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:6.31M
Value:$29.83M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:6.31M
Value:$29.83M
REDMILE GROUP, LLC
Shares:5.54M
Value:$26.2M
Summary
Showing Top 3 of 66
About Shattuck Labs, Inc.
https://www.shattucklabs.comShattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1M ▲ | $11.72M ▼ | $-10.06M ▲ | -1.01K% ▼ | $-0.14 ▲ | $-9.14M ▲ |
| Q2-2025 | $0 | $12.1M ▼ | $-12.46M ▲ | 0% | $-0.24 ▲ | $-11.53M ▲ |
| Q1-2025 | $0 | $13.45M ▼ | $-13.7M ▲ | 0% | $-0.27 ▲ | $-13.45M ▲ |
| Q4-2024 | $0 ▼ | $19.64M ▼ | $-18.68M ▼ | 0% ▲ | $-0.37 ▼ | $-18.7M ▼ |
| Q3-2024 | $3M | $19.96M | $-16.68M | -556.39% | $-0.33 | $-16.97M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $42.55M ▼ | $100.33M ▲ | $7.09M ▼ | $93.24M ▲ |
| Q2-2025 | $50.47M ▼ | $64.37M ▼ | $7.35M ▼ | $57.02M ▼ |
| Q1-2025 | $60.9M ▼ | $77.17M ▼ | $9.58M ▼ | $67.59M ▼ |
| Q4-2024 | $72.99M ▼ | $91.05M ▼ | $11.42M ▼ | $79.63M ▼ |
| Q3-2024 | $90.06M | $111.72M | $15.14M | $96.58M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-10.06M ▲ | $-8.93M ▲ | $-43.49M ▼ | $44.5M ▲ | $-7.92M ▲ | $-9M ▲ |
| Q2-2025 | $-12.46M ▲ | $-10.43M ▲ | $0 ▼ | $0 ▲ | $-10.43M ▼ | $-10.43M ▲ |
| Q1-2025 | $-13.7M ▲ | $-12.03M ▲ | $15.6M ▼ | $-57K ▲ | $3.51M ▼ | $-12.03M ▲ |
| Q4-2024 | $-18.68M ▼ | $-17.37M ▼ | $31M ▲ | $-72K ▼ | $13.56M ▲ | $-17.37M ▼ |
| Q3-2024 | $-16.68M | $-16.07M | $-821K | $23K | $-16.86M | $-16.11M |
Revenue by Products
| Product | Q2-2024 | Q3-2024 | Q4-2024 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Taylor H. Schreiber
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 16
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:6.31M
Value:$29.83M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:6.31M
Value:$29.83M
REDMILE GROUP, LLC
Shares:5.54M
Value:$26.2M
Summary
Showing Top 3 of 66